OZILTUS
LaunchmAbdenosumab-mobz
BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OZILTUS (denosumab-mobz) is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OZILTUS (denosumab-mobz) is a monoclonal antibody that blocks RANK ligand to inhibit osteoclast activation and bone resorption. This RANK ligand inhibitor is administered subcutaneously and represents a biosimilar or follow-on biologic entry in the denosumab class. The drug targets patients requiring bone-protective therapy across multiple indications.
Launch
Early-stage launch product with moderate competitive pressure (30/100) creating entry-level and mid-market commercial opportunity for field teams and product specialists.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OZILTUS at launch offers entry and mid-career positions primarily in commercial execution, market access, and medical education roles. Early adopters will shape market positioning in a competitive landscape, with career momentum tied to competitive performance and reimbursement success.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.